Michael Conick Hanley
Geen lopende functies
Vermogen: 47 017 $ op 30-04-2024
Profiel
Michael Conick Hanley worked as the Chief Business Officer at Spyre Therapeutics, Inc. from 2022 to 2023.
Prior to that, he was the Chief Commercial Officer & Vice President at Esteve Pharmaceuticals S.A.
from 2018 to 2019 and the Group Vice President-Marketing at Horizon Therapeutics Plc from 2015 to 2017.
Hanley completed his undergraduate degree at Notre Dame University and earned an MBA from Kellogg School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SPYRE THERAPEUTICS, INC
0.00% | 23-02-2023 | 1 448 ( 0.00% ) | 47 017 $ | 30-04-2024 |
Eerdere bekende functies van Michael Conick Hanley
| Bedrijven | Functie | Einde |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 14-04-2023 |
Esteve Pharmaceuticals S.A.
 Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 01-09-2019 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Verkoop & Marketing | 01-06-2017 |
Opleiding van Michael Conick Hanley
| Kellogg School of Management | Masters Business Admin |
| Notre Dame University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Esteve Pharmaceuticals S.A.
Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |